@SteveYoder

CEO of @PierisPharma

[@SteveYoder @YoderSteve]

It's rewarding to see our second lead IO program enter the clinic, and we look forward to hopefully sharing some initial data from this study next year!

[Palvella Therapeutics @PalvellaTX]

We are excited to announce the dosing of the first patient in the phase 1/2 trial of PRS-344/S095012, a 4-1BB/PD-L1 bispecific we are developing with @Servier for the treatment of solid tumors! https://t.co/eJjsm76nrO

[@SteveYoder @YoderSteve]

This week at Pieris has been all about IPF patients and will culminate with tomorrow's fundraising walk for many of us -- we've implemented a corporate match up to $5k, so any support will have twice the impact for pulmonary fibrosis patients!

[Palvella Therapeutics @PalvellaTX]

We are looking forward to participating in the the #PFFWalk tomorrow and are close to reaching our goal of raising $5K for @PFFORG! Every dollar makes a differences for PF patients. Check on our progress here: https://t.co/5rCqpcBj26

[@SteveYoder @YoderSteve]

This morning, I had the pleasure to interview Malcolm "Mal" Doyle in front of a packed virtual audience of Pieris colleagues. Everyone is more inspired to develop PRS-220 as a result. https://t.co/eLEo0AKPgK

[Palvella Therapeutics @PalvellaTX]

Thank you to #IPF ambassador Mal for an inspiring conversation with our team today about the life of an IPF patient (and to the @PFFORG for organizing)! Patients like you are at the core of our mission, and we are honored that you could join us virtually for this event!

[@SteveYoder @YoderSteve]

It's great to see continued recognition of the great potential for an inhaled CTGF intervention for #pulmonaryfibrosis patients

[Pulmonary Fibrosis News @pulmonaryfibros]

PRS-220, Pieris’ experimental inhaled #IPFtherapy, showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab. https://t.co/OCIgud9vQb

#PFNews #pulmonaryfibrosisawareness #pulmonaryfibrosisnews #livingwithPF #PFAwarenessMonth #PFresearch #IPF

[Palvella Therapeutics @PalvellaTX]

See PRS-220, our inhaled CTGF antagonist for #IPF, penetrate deep into a fibrotic mouse lung.

Learn more about PRS-220 in our #ERS2021 poster here: https://t.co/0YrnwkKIbo. Thanks to @GubraBiotech for collaborating with us to generate these images using light sheet microscopy!

[@SteveYoder @YoderSteve]

“Excited to share first preclinical data for PRS-220 at #erscongress 2021. We believe this novel inhaled approach may significantly improve the lives of patients suffering from #IPF and #longcovid. We look forward to beginning clinical trials next year.”

[@SteveYoder @YoderSteve]

Delighted Shane Olwill was promoted to Chief Development Officer @PierisPharma. Our pipeline wouldn’t be where it is w/o Shane’s scientific leadership. I fondly recall him whiteboarding 4-1BB concepts before we were public. Those concepts spurred a new era of Tx for cancer pts!

[@SteveYoder @YoderSteve]

It’s a pleasure to welcome Tim Demuth MD PhD to @PierisPharma as Chief Medical Officer. Great track record developing next-gen bx, deep expertise in oncology and scientific depth in several disease areas. Perfect fit for Pieris as we advance inhaled biologics and IO bispecifics.

[Palvella Therapeutics @PalvellaTX]

Tomorrow at 11:20 EDT, Dr. Shane Olwill will be participating on a panel, Moving Beyond Monoclonals: The Potential of Multispecific Therapies, at the @WilliamBlair Biotech Focus Conference. Tune in here: https://t.co/jR7GcextK8

[Palvella Therapeutics @PalvellaTX]

Thank you to Huber Aiwanger, Bavarian State Minister of Economic Affairs, Regional Development and Energy, for visiting our Hallbergmoos site today. We are grateful to have been selected for a ~$17M grant to evaluate PRS-220 in #LongCovid!

[@SteveYoder @YoderSteve]

Excited to reveal PRS-220, an inhaled treatment for IPF, today and proud @PierisPharma selected to receive ~$17M grant from the Bavarian government to additionally evaluate the program for #longcovid! Gratifying to leverage our respiratory platform once again for #improvinglives

[Palvella Therapeutics @PalvellaTX]

We are excited to announce that FDA has granted orphan drug designation to cinrebafusp alfa for the treatment of HER2-high and HER2-low expressing gastric cancers! https://t.co/glD88oS3PD

[Palvella Therapeutics @PalvellaTX]

As a 4-1BB leader with the first ever 4-1BB-based bispecific to enter clinical development and several other 4-1BB-based programs in our pipeline, we are excited to see the buzz around this promising target at the upcoming #ASCO2021 meeting!🚀 https://t.co/CjODZISBfn

[Palvella Therapeutics @PalvellaTX]

We are excited to announce a multi-program research collaboration and license agreement with @Genentech to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage our proprietary Anticalin technology! https://t.co/SRy5EDr92q

[@SteveYoder @YoderSteve]

Very proud of the entire team at @PierisPharma for attracting another stellar partner like @genentech. It's an honor to be collaborating with the Roche Group once again! https://t.co/YhT16EcrlX

[Palvella Therapeutics @PalvellaTX]

Pieris is proud to have signed the @MassBio CEO Pledge for a More Equitable & Inclusive Life Sciences Industry. We are committed to working with @MassBio on this important life sciences #inclusion initiative.

[Palvella Therapeutics @PalvellaTX]

Today, we at Pieris are taking a stand to support #DiversityDay2020 across Germany! We passionately believe that differences make the difference. We commit to creating a work environment where all different perspectives and cultures can flourish.

[Palvella Therapeutics @PalvellaTX]

Tomorrow at 1PM EDT we will be participating in the @SoleburyTrout Virtual Global Healthcare Conference Series! To access the live presentation webcast: https://t.co/b49yDX9GrQ

[Palvella Therapeutics @PalvellaTX]

Tomorrow, Feb. 20 at 2PM ET: Listen to a replay of Dr. Geoff Ku's presentation of PRS-343 phase 1 data at #SITC2019. Dr. Ku will be available for a live Q&A session after the replay. To participate in the replay webinar, sign up here: https://t.co/f6H8hSIy6y

[Palvella Therapeutics @PalvellaTX]

Tune in to our R&D Day tomorrow to hear from leading #immunooncology and #respiratory KOLs and $PIRS management about our exciting pipeline developments! https://t.co/ZDzu7VRGE2